

Mortality in Adult-Onset Autoimmune Diabetes Is Associated With Poor Glycemic Control

Results from the HUNT Study

LISA OLSSON, PHD^{1,2}
VALDEMAR GRILL, MD, PHD³
KRISTIAN MIDTHJELL, MD, PHD⁴

ANDERS AHLBOM, PHD²
TOMAS ANDERSSON, BSC^{2,5}
SOFIA CARLSSON, PHD²

OBJECTIVE—Knowledge on mortality in autoimmune diabetes with adult onset is limited. We compared mortality in adult-onset autoimmune diabetes and type 2 diabetes, taking into account metabolic risk factors, HbA_{1c}, lifestyle, and socioeconomic factors.

RESEARCH DESIGN AND METHODS—Participants of the population-based HUNT2 Study (second survey of the Norwegian HelseUndersøkelsen i Nord-Trøndelag Study; $n = 64,264$) were followed up prospectively for mortality in the Cause of Death Registry (1995–2009). Diabetes with onset ≥ 35 years was classified as autoimmune diabetes in adults if anti-GAD was positive ($n = 208$) and as type 2 diabetes if anti-GAD was negative ($n = 2,425$). Hazard ratios (HRs) of mortality from all-causes, cardiovascular disease (CVD), and ischemic heart disease (IHD) were calculated using the Cox proportional hazards model.

RESULTS—Prevalence of the metabolic syndrome was lower in autoimmune diabetes than in type 2 diabetes (55 vs. 77%, $P < 0.001$). Still, autoimmune diabetes was associated with an increased risk of mortality from all-causes (HR 1.55 [95% CI 1.25–1.92]), CVD (1.87 [1.40–2.48]), and IHD (2.39 [1.57–3.64]), equally high as in type 2 diabetes in analyses where individuals without diabetes were used as the reference group. The increased risk was not explained by overweight, lifestyle, socioeconomic position, or presence of the metabolic syndrome. Excess mortality was primarily observed in individuals with elevated HbA_{1c}.

CONCLUSIONS—Mortality in autoimmune diabetes was as high as in type 2 diabetes, despite a more favorable baseline metabolic risk profile. Excess risk was associated with poor glycemic control. The results from this study, the largest so far on mortality in autoimmune diabetes in adults, underscore the importance of optimal treatment modalities to improve survival in adult-onset autoimmune diabetes.

Diabetes Care 36:3971–3978, 2013

All forms of diabetes are associated with increased mortality, primarily from cardiovascular disease (CVD) and, in particular, ischemic heart disease (IHD) (1–3). A meta-analysis of 102 prospective studies reported that diabetes

confers about a twofold excess risk of CVD, independent of other risk factors (4). Prolonged exposure to hyperglycemia is a well-recognized etiological factor. Hyperglycemia initiates a complex chain of events that damage blood vessels and

potentially accelerate the atherosclerotic process (5). However, other factors are also bound to be important and may modify the total risk differently in different forms of diabetes. Hence, excess mortality in type 2 diabetes has also been attributed to traditional risk factors, such as obesity and other components of the metabolic syndrome (6,7), and to socioeconomic factors (8).

The effect of juvenile-onset type 1 diabetes on CVD and mortality is well recognized (1). Less so is the effect of autoimmune diabetes with adult onset. Still, autoimmune diabetes constitutes a significant part of diabetes, especially in the phenotype termed latent autoimmune diabetes in adults (LADA), which is estimated to account for ~10% of all diabetes (9–11). Autoimmune diabetes is characterized by antibodies against the insulin-producing β -cells (9,12). Compared with “classic” type 1 diabetes, LADA progresses more slowly and is typically not treated with insulin at the time of diagnosis.

On one hand, fewer features of the metabolic syndrome have been reported in individuals with adult-onset autoimmune diabetes than in individuals with type 2 diabetes (13–17), and this may indicate a lower risk of complications. On the other hand, worse glycemic control has been suggested in LADA patients than in patients with type 2 diabetes (15,18–20), something that could put these individuals at increased risk of complications and mortality. Only two previous studies, based on Australian and Finnish populations, have addressed mortality in autoimmune diabetes in adults/LADA (18,21). In addition, a recent U.S. article (22) reported markedly worse prognosis among normal-weight compared with overweight diabetic patients. They speculated about the role of LADA, but did not have information on indicators of autoimmunity to separate patients with LADA from those with type 2 diabetes.

From the large population-based and prospective Norwegian HUNT Study

From the ¹Centre for Health Equity Studies, Stockholm University/Karolinska Institutet, Stockholm, Sweden; the ²Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; the ³Department of Cancer Research and Molecular Medicine, Faculty of Medicine, the Norwegian University of Science and Technology, and Department of Endocrinology, St. Olav University Hospital, Trondheim, Norway; the ⁴HUNT Research Centre, Department of Community Medicine and General Practice, Faculty of Medicine, the Norwegian University of Science and Technology, Levanger, Norway; and the ⁵Centre for Occupational and Environmental Medicine, Stockholm County Council, Stockholm, Sweden.

Corresponding author: Lisa Olsson, lisa.olsson@chess.su.se.

Received 7 March 2013 and accepted 20 July 2013.

DOI: 10.2337/dc13-0564

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-0564/-/DC1>.

© 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

(an acronym for the Norwegian name: HelseUndersøkelsen i Nord-Trøndelag), in conjunction with the Cause of Death Registry, it is possible to identify different forms of diabetes and to analyze mortality and cause of death. The size of the study would provide data for the largest study to date on mortality in autoimmune diabetes in adults.

Here, we aimed to investigate the risk of all-cause, CVD, and IHD mortality in autoimmune diabetes in adults and type 2 diabetes, taking into account the influence of metabolic risk factors, glycemic control, lifestyle, and socioeconomic factors.

RESEARCH DESIGN AND METHODS

Study population

The HUNT Study consists of three surveys in 1984–2008 where the entire population of the Norwegian County of Nord-Trøndelag was invited to participate. In 1995–1997, 66,140 men and women (71.2%), aged 20 years or older, participated in the second of these surveys (HUNT2), consisting of questionnaires, physical examinations, and blood sampling. Individuals with diabetes were invited to a supplementary examination during which information on anti-GAD, fasting glucose, and HbA_{1c} was gathered. The design of the HUNT Study has previously been presented in detail (23). Among the participants of the HUNT2 survey, complete baseline information on diabetes status was available for 64,815 individuals. During 1995–2008, 3,184 individuals with diabetes were identified, including 208 adults with autoimmune diabetes and 2,425 with type 2 diabetes. Our final study population consisted of 64,264 individuals (2,633 with autoimmune and type 2 diabetes together with 61,631 individuals without diabetes).

We monitored the study population for mortality between 1995 and 2009 by linkage to the Norwegian Cause of Death Registry. In addition to all-cause mortality, we identified individuals with CVD (ICD-10 codes I00–I99 and ICD-9 codes 390–459) and IHD (ICD-10 codes I20–I25 and ICD-9 codes 410–414) as the underlying or contributing cause of death. Migration from the Nord-Trøndelag County was low (<1%) during this time period, as shown in a previous study (24), and was considered negligible.

The HUNT Study and the mortality follow-up were approved by the Norwegian Data Inspectorate and the Regional Medical Research Ethical Committee. The participants of the HUNT Study gave written informed consent.

Classification of diabetes

Individuals with diabetes were identified by questionnaire. Fasting blood samples from all diagnosed diabetic individuals were obtained through the clinical investigation of HUNT and analyzed for anti-GAD, as previously described (25). Antibody levels were expressed as an antibody index relative to a standard serum. An index of ≥ 0.08 was considered positive. This cutoff was used to achieve the highest possible specificity (1.00) with an acceptable corresponding sensitivity (0.64). Anti-GAD values are reported in World Health Organization (WHO) units (0.08 antibody index = 43 WHO units/mL).

Diabetes with age at onset ≥ 35 years was classified as autoimmune diabetes in adults ($n = 208$) if anti-GAD was positive and as type 2 diabetes ($n = 2,425$) if anti-GAD was negative. Anti-GAD–positive individuals aged <35 years at onset were classified as having “classic” type 1 diabetes ($n = 66$). To distinguish LADA from all autoimmune diabetes in adults, we included a criterion of insulin independence at diagnosis as an indicator of slow onset, as suggested previously (26). In the HUNT Study, however, information on insulin treatment is available yearly, and not monthly, and we defined LADA case subjects as individuals free of insulin during the year of diagnosis (rather than free of insulin use up to 6 months after diagnosis). We used information on insulin treatment (yes/no) and year of initiation, available for 76% ($n = 159$) of all individuals with autoimmune diabetes, and classified anti-GAD–positive individuals (with onset ≥ 35 years) as having LADA if they reported not being treated with insulin during the year of diagnosis ($n = 141$). On the basis of this criterion, 89% of our case subjects with autoimmune diabetes with adult onset (with information on insulin treatment) were classified as having LADA.

Metabolic risk factors

Examinations in HUNT included measurements of height, weight, waist and hip circumference, blood pressure, total cholesterol, HDL-cholesterol, and triglycerides. Hypertension was defined as a blood pressure >140/90 mmHg or as current

use of antihypertensive medication. Criteria for the metabolic syndrome were applied as recommended by the International Diabetes Federation (27). Hence, central obesity (waist circumference ≥ 94 cm for men and ≥ 80 cm for women) was required, plus at least two of the following four components: raised triglycerides (≥ 1.7 mmol/L) or specific treatment for this lipid abnormality, reduced HDL-cholesterol (<1.03 mmol/L in men and <1.29 mmol/L in women) or specific treatment for this lipid abnormality, raised blood pressure (systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg) or treatment for previously diagnosed hypertension, or raised fasting plasma glucose (≥ 5.6 mmol/L) or previously diagnosed type 2 diabetes. Information on pharmacological treatment for lipid abnormalities was not available, but such treatment was uncommon in Norway at the time.

Lifestyle, socioeconomic factors, and family history of diabetes

We used questionnaire information on physical activity, smoking, and alcohol consumption (referred to as lifestyle factors) to classify participants as physically active or inactive; never, former, or current smokers; and as abstainers, occasional, low, moderate, or high consumers of alcohol. Participants were also classified as having an educational level corresponding to primary school, upper secondary school, or university, and as having a low-grade (manual workers), middle (nonmanual employees, farmers, fishermen, other self-employment), or high-grade (higher- and lower-grade professionals, administrators, and officials) occupational position. Information on family history of diabetes was collected by separate questions on diabetes in parents, siblings, and children, as well as age at onset of diabetes for each relative.

Statistical analyses

We used left-truncated Cox proportional hazards models to estimate hazard ratios (HRs) and corresponding 95% CI for mortality from all causes, CVD, and IHD in relation to diabetes status at baseline. Person-years of follow-up were accumulated from age at baseline until age at death or until age at the end of follow-up, December 31, 2009. We used age (in years) as the underlying time scale in the Cox model, which provides efficient adjustment for confounding from age (28). Kaplan-Meier curves were estimated to

illustrate all-cause mortality by diabetes type.

To take advantage of the repeated measures, the analyses were time-dependent; that is, we updated the baseline (HUNT2) information on diabetes status using information on diabetes onset from the HUNT3 survey. This means that the analyses allow for individuals who developed diabetes during follow-up (i.e., sometime between participating in HUNT2 and HUNT3) to change exposure (i.e., diabetes) status during follow-up. Of the 2,633 individuals with diabetes, 1,583 were identified at baseline (i.e., in the HUNT2 survey, 1995–1997), whereas 1,050 individuals without diabetes at baseline developed diabetes sometime between the HUNT2 and the HUNT3 surveys. These individuals were identified at the time of the third HUNT survey in 2006–2008 (HUNT3), and time exposed was accounted from year of diagnosis.

In Table 2, HRs of mortality by diabetes status are reported after adjustment for age and sex (model 1), age, sex, BMI, waist-to-hip ratio, physical activity, smoking, alcohol consumption, educational level, and family history of diabetes (model 2), and additionally, adjustment for the metabolic syndrome (as a composite variable) and LDL-cholesterol (model 3). The proportional hazard assumption was fulfilled for all these covariates at the Cox regression analyses, with use of the test for all time-dependent covariate variables added. All analyses were conducted using SAS 9.2 software (SAS Institute Inc., Cary, NC).

RESULTS

Characteristics of the study population

The 64,264 participants contributed to the analyses with 836,586 person-years. During the 14 years of follow-up, there were 10,537 deaths, 5,183 from CVD, and of those, 2,301 from IHD. Mean follow-up time was 13.2 years among individuals without diabetes and 9.1 years among those with diabetes. During follow-up, 15% among those without diabetes died (17% among men and 13% among women) compared with 33% among those with diabetes (33% among men and 34% among women). Overall mortality was 18% lower in the HUNT population than in the general population of Norway compared with age-specific mortality rates for Norway obtained from WHO (29).

A comparison of individuals with and without diabetes showed those without diabetes were younger, more physically active and leaner, had lower blood pressure and more “healthy” blood lipids, and were less likely to have a low educational background (Table 1). A comparison of adult-onset autoimmune diabetes with type 2 diabetes showed the former was associated with less central obesity, lower levels of triglycerides, and higher HDL-cholesterol levels. Accordingly, prevalence of the metabolic syndrome was lower in autoimmune diabetes, at 55 vs. 77%. Mean duration of diabetes was longer and HbA_{1c} levels were higher in autoimmune diabetes compared with type 2 diabetes.

Increased mortality in adult-onset autoimmune diabetes and type 2 diabetes

Autoimmune diabetes was associated with excess mortality from all-causes, CVD, and IHD compared with individuals without diabetes (Table 2). Increased risks were seen in men and women. These results were similar to those seen for type 2 diabetes. Associations were seen after adjustment for age, sex, BMI, physical activity, smoking, alcohol consumption, educational level, family history of diabetes (model 2), and the metabolic syndrome (model 3). In addition to the analyses where the metabolic syndrome was included as a combined variable (model 3), we also performed analyses

Table 1—Baseline characteristics of the study population from the HUNT2 survey in 1995–1997

Characteristics*	No known diabetes	Autoimmune diabetes in adults	Type 2 diabetes	P†
<i>n</i>	61,631	208	2,425	
Men	46.7	49.0	49.9	0.82
Age (years)	49.3 (17.1)	64.1 (13.3)	62.4 (13.1)	0.082
BMI (kg/m ²)	26.2 (4.0)	28.2 (4.7)	29.7 (4.7)	<0.001
Physically inactive	24.2	28.2	32.4	0.44
Current smoker	29.8	17.8	20.8	0.59
High alcohol consumption	3.1	2.0	2.6	0.21
Low educational level	35.7	54.8	58.5	0.165
Family history of diabetes	14.2	35.6	41.2	0.111
Waist-to-hip ratio	0.84 (0.08)	0.88 (0.08)	0.90 (0.08)	0.002
Obese (BMI ≥30 kg/m ²)	15.3	29.1	42.4	<0.001
Central obesity	44.7	69.8	79.7	0.001
Blood pressure (mmHg)				
Systolic	137.2 (21.5)	150.7 (23.0)	151.4 (23.1)	0.68
Diastolic	80.0 (12.2)	82.9 (12.3)	85.7 (12.6)	0.002
Hypertension	23.7	48.6	52.3	0.30
Triglycerides (mmol/L)	1.72 (1.09)	2.17 (1.60)	2.62 (1.63)	0.001
Cholesterol (mmol/L)	5.88 (1.26)	5.96 (1.26)	6.28 (1.26)	0.001
HDL-cholesterol (mmol/L)	1.38 (0.39)	1.31 (0.47)	1.19 (0.36)	<0.001
Metabolic syndrome	23.8‡	54.8	77.0	<0.001
Previous CVD event§	7.3	18.3	21.6	0.26
Age at onset (years)	—	58.5 (11.0)	60.7 (11.0)	0.007
Duration of diabetes (years)	—	14.7 (8.6)	10.9 (7.8)	<0.001
Insulin treatment	—	57.2	24.1	<0.001
HbA _{1c} (%)	—	8.3 (2.1)	7.7 (1.7)	<0.001
HbA _{1c} (mmol/mol)	—	67 (23.0)	61 (18.6)	
Fasting glucose (mmol/L)	—	8.7 (3.7)	8.4 (2.5)	0.140
C-peptide, median (IQR) (pmol/L)	—	440.0 (854.0)	791.0 (664.0)	<0.001

*Data are means (SD) or percentages, unless otherwise indicated. Data on C-peptide are expressed as median and interquartile range because the distribution of C-peptide was skewed. †P values for difference between case subjects with autoimmune diabetes and type 2 diabetes using Student *t* test (means), Kruskal-Wallis test (medians), and χ^2 test (proportions). ‡Measurement of glucose included in the definition of the metabolic syndrome was nonfasting for individuals with no known diabetes. §Self-reported myocardial infarction, stroke, or angina pectoris.

Table 2—HRs of mortality from all-causes, CVD, and IHD in adult-onset autoimmune diabetes, type 2 diabetes, and LADA compared with individuals without diabetes

	Number of deaths/person-years in individuals with diabetes (n/N)				Model 1			Model 2			Model 3		
	Number of deaths/person-years in individuals without diabetes (n/N)		Women (age adjusted)		HR (95% CI)		HR (95% CI)		HR (95% CI)		HR (95% CI)		
	Men (age adjusted)	HR (95% CI)	All individuals	HR (95% CI)	All individuals	HR (95% CI)	All individuals	HR (95% CI)	All individuals	HR (95% CI)	All individuals	HR (95% CI)	
Autoimmune diabetes in adults vs. no diabetes													
All-cause mortality	9,478/812,301	1.49 (1.11–2.01)	39/1,076	1.63 (1.19–2.23)	83/2,048	1.56 (1.26–1.93)	1.61 (1.28–2.03)	1.61 (1.28–2.03)	1.61 (1.27–2.03)	1.61 (1.27–2.03)	1.61 (1.27–2.03)	1.61 (1.27–2.03)	
CVD mortality	4,552/812,301	1.86 (1.27–2.72)	21/1,076	1.93 (1.25–2.96)	48/2,048	1.89 (1.42–2.52)	1.92 (1.39–2.64)	1.92 (1.39–2.64)	1.94 (1.41–2.68)	1.94 (1.41–2.68)	1.94 (1.41–2.68)	1.94 (1.41–2.68)	
IHD mortality	1,973/812,301	2.17 (1.23–3.83)	10/1,076	2.70 (1.44–5.03)	22/2,048	2.44 (1.61–3.72)	2.49 (1.58–3.93)	2.49 (1.58–3.93)	2.58 (1.64–4.07)	2.58 (1.64–4.07)	2.58 (1.64–4.07)	2.58 (1.64–4.07)	
Type 2 diabetes vs. no diabetes													
All-cause mortality	9,478/812,301	1.30 (1.18–1.44)	428/11,040	1.56 (1.41–1.72)	830/21,820	1.43 (1.33–1.53)	1.41 (1.30–1.53)	1.41 (1.30–1.53)	1.41 (1.31–1.53)	1.41 (1.31–1.53)	1.41 (1.31–1.53)	1.41 (1.31–1.53)	
CVD mortality	4,552/812,301	1.55 (1.36–1.77)	265/11,040	1.90 (1.67–2.16)	502/21,820	1.73 (1.58–1.90)	1.69 (1.53–1.87)	1.69 (1.53–1.87)	1.70 (1.53–1.89)	1.70 (1.53–1.89)	1.70 (1.53–1.89)	1.70 (1.53–1.89)	
IHD mortality	1,973/812,301	1.88 (1.57–2.23)	120/11,040	2.62 (2.16–3.18)	260/21,820	2.17 (1.91–2.47)	2.08 (1.80–2.40)	2.08 (1.80–2.40)	2.11 (1.82–2.44)	2.11 (1.82–2.44)	2.11 (1.82–2.44)	2.11 (1.82–2.44)	
LADA vs. no diabetes													
All-cause mortality	9,478/812,301	1.40 (0.98–1.99)	26/741	1.65 (1.12–2.42)	57/1,437	1.50 (1.16–1.95)	1.58 (1.20–2.08)	1.58 (1.20–2.08)	1.57 (1.19–2.07)	1.57 (1.19–2.07)	1.57 (1.19–2.07)	1.57 (1.19–2.07)	
CVD mortality	4,552/812,301	1.56 (0.96–2.53)	14/741	1.86 (1.10–3.15)	31/1,437	1.68 (1.18–2.40)	1.74 (1.18–2.57)	1.74 (1.18–2.57)	1.77 (1.20–2.60)	1.77 (1.20–2.60)	1.77 (1.20–2.60)	1.77 (1.20–2.60)	
IHD mortality	1,973/812,301	2.21 (1.19–4.11)	8/741	2.89 (1.44–5.81)	18/1,437	2.54 (1.60–4.05)	2.56 (1.56–4.21)	2.56 (1.56–4.21)	2.66 (1.62–4.37)	2.66 (1.62–4.37)	2.66 (1.62–4.37)	2.66 (1.62–4.37)	

Model 1 is adjusted for age and sex. Model 2 is adjusted for age, sex, BMI, waist-to-hip ratio, physical activity, smoking, alcohol consumption, educational level, and family history of diabetes. Model 3 is adjusted for the same covariates as model 2 and LDL-cholesterol and the metabolic syndrome.

that were adjusted for the components of the metabolic syndrome in which each one of these was included separately in the model. This adjustment did not significantly affect the estimates; for example, no effect of blood pressure or cholesterol levels was noted when analyzed separately in relation to mortality.

In stratified analyses, autoimmune diabetes and type 2 diabetes were both associated with excess mortality across levels of BMI; for example, in autoimmune diabetes, the HR of CVD mortality (adjusted for age and sex) was 1.69 (95% CI 0.97–2.95) in individuals with a BMI <25 kg/m², 2.00 (95% CI 1.30–3.08) in overweight (BMI 25–29.9 kg/m²), and 1.88 (95% CI 1.09–3.26) in obese (BMI ≥30 kg/m²) individuals. The cohort was also stratified according to educational level and occupational position, and increased mortality was seen across levels of education and occupation (results not shown). For these stratified analyses, additional adjustment for lifestyle factors or metabolic factors did not change the results. At baseline, 18% of individuals with autoimmune diabetes and 22% of those with type 2 diabetes reported a previous CVD event (i.e., self-reported myocardial infarction, stroke, or angina). Subgroup analyses in individuals with and without prior CVD events found the age- and sex-adjusted HR of CVD mortality in autoimmune diabetes was 1.55 (95% CI 1.06–2.27) in individuals without and 2.80 (95% CI 1.82–4.30) in individuals with a previous CVD event, and corresponding results for type 2 diabetes were, respectively, HR 1.68 (95% CI 1.48–1.91) and 1.46 (95% CI 1.28–1.67).

Kaplan-Meier curves of all-cause mortality rates were similar in autoimmune diabetes and type 2 diabetes (Supplementary Fig. 1). HRs of all-cause, CVD, and IHD mortality in autoimmune diabetes compared with type 2 diabetes were estimated at HRs of 1.02 (95% CI 0.81–1.28), 0.99 (95% CI 0.74–1.33), and 0.88 (95% CI 0.57–1.36), respectively, after adjustment for age, sex, and duration of diabetes. The associations were somewhat attenuated after adjustment for duration of diabetes; HRs without adjustment for duration of diabetes were 1.11 (95% CI 0.88–1.39) for all-cause mortality, 1.06 (95% CI 0.79–1.43) for CVD mortality, and 0.95 (95% CI 0.62–1.47) for IHD mortality. The analyses of autoimmune diabetes versus type 2 diabetes were, however, based on small numbers, and we cannot

Table 3—Risk of mortality in adult-onset autoimmune diabetes and type 2 diabetes compared with individuals without known diabetes, stratified on levels of HbA_{1c}, fasting glucose, and insulin treatment

	HbA _{1c}		Fasting glucose		Insulin treatment	
	<7% (<53 mmol/mol)	≥7% (≥53 mmol/mol)	<8 mmol/L	≥8 mmol/L	No insulin treatment	Insulin treatment
	Number of deaths/person-years (n/N)	Number of deaths/person-years (n/N)	Number of deaths/person-years (n/N)	Number of deaths/person-years (n/N)	Number of deaths/person-years (n/N)	Number of deaths/person-years (n/N)
	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)
Autoimmune diabetes vs. no diabetes						
All-cause mortality	18/564	62/1,285	32/761	41/886	33/712	30/1,031
	1.24 (0.78–1.96)	1.75 (1.36–2.24)	1.38 (0.97–1.95)	1.86 (1.37–2.52)	1.35 (0.96–1.90)	1.59 (1.11–2.27)
CVD mortality	10/564	35/1,285	21/761	21/886	20/712	14/1,031
	1.36 (0.73–2.55)	2.17 (1.56–3.03)	1.72 (1.12–2.65)	2.37 (1.54–3.64)	1.55 (1.00–2.41)	1.81 (1.07–3.05)
IHD mortality	2/564	19/1,285	8/761	12/886	10/712	9/1,031
	0.90 (0.23–3.60)	3.13 (1.99–4.92)	1.99 (0.99–3.99)	3.52 (1.99–6.21)	2.23 (1.20–4.15)	2.82 (1.46–5.43)
Type 2 diabetes vs. no diabetes						
All-cause mortality	221/6,706	560/12,222	288/7,203	335/7,555	458/13,586	197/5,301
	1.23 (1.08–1.41)	1.62 (1.49–1.76)	1.35 (1.20–1.52)	1.56 (1.40–1.74)	1.25 (1.13–1.37)	1.85 (1.61–2.13)
CVD mortality	136/6,706	342/12,222	180/7,203	202/7,555	271/13,586	120/5,301
	1.42 (1.19–1.68)	2.07 (1.86–2.31)	1.61 (1.39–1.87)	2.08 (1.81–2.40)	1.45 (1.29–1.64)	2.48 (2.07–2.97)
IHD mortality	73/6,706	179/12,222	94/7,203	110/7,555	141/13,586	68/5,301
	1.83 (1.45–2.31)	2.69 (2.30–3.13)	2.05 (1.67–2.52)	2.78 (2.29–3.37)	1.73 (1.46–2.06)	3.31 (2.60–4.22)

Adjusted for age and sex. The most recent information on HbA_{1c}, fasting glucose, and insulin treatment was used (i.e., from HUNTT3 if available, otherwise from HUNTT2).

exclude a possible difference between types of diabetes.

Mortality in LADA

Increased all-cause and CVD mortality was seen also when autoimmune diabetes was restricted to LADA (Table 2). The age and sex adjusted HRs were 1.50 (95% CI 1.16–1.95) for all-cause mortality, 1.68 (95% CI 1.18–2.40) for CVD mortality, and 2.54 (95% CI 1.60–4.05) for IHD mortality. This excess risk was not explained by metabolic risk factors, lifestyle, or socioeconomic factors.

Glycemic control

Excess mortality in autoimmune diabetes and type 2 diabetes was mainly seen in individuals with HbA_{1c} ≥7% (≥53 mmol/mol) (Table 3). Mortality risks were also higher in individuals with higher fasting glucose (individuals being dichotomized according to the median of fasting glucose levels). Figure 1 displays HRs of all-cause and CVD mortality by HbA_{1c} levels and shows that HbA_{1c} was a strong indicator of mortality risk for both autoimmune diabetes and type 2 diabetes. For every unit of HbA_{1c}, the HR of CVD mortality increased, with 1.22 (95% CI 1.06–1.40) in autoimmune diabetes and 1.15 (95% CI 1.10–1.20) in type 2 diabetes. The analyses in autoimmune diabetes were, however, limited by small numbers.

Duration of diabetes

Mortality increased with diabetes duration. For every year with diabetes, the HR for all-cause mortality was 1.02 (95% CI 0.99–1.05) in autoimmune diabetes and 1.03 (95% CI 1.02–1.04) in type 2 diabetes. The effect of duration on mortality in autoimmune diabetes was seen mainly in individuals with high HbA_{1c}, with a HR of 1.02 (95% CI 0.99–1.05) vs. 0.97 (95% CI 0.88–1.06). A longer duration of diabetes was seen in insulin-treated versus non-insulin-treated individuals, and the HRs of all-cause mortality for insulin-treated versus non-insulin-treated individuals were 0.83 (95% CI 0.49–1.40) in autoimmune diabetes and 1.18 (95% CI 0.98–1.43) in type 2 diabetes, adjusted for age, sex, duration of diabetes, and HbA_{1c}.

CONCLUSIONS—Our findings indicate that mortality in autoimmune diabetes in adults is at least as high as in type 2 diabetes, including a more than twofold increased risk of death from IHD.




Figure 1—HR of all-cause and CVD mortality in adult-onset autoimmune diabetes and type 2 diabetes by levels of HbA_{1c} (reference HbA_{1c} <7% [<53 mmol/mol]).

The excess risk was seen in men and women and was not explained by components of the metabolic syndrome or by socioeconomic factors but appeared for the major part to be associated with poor glycaemic control.

We confirm previous findings (15,18–20) of worse glycaemic control, as measured by HbA_{1c}, in autoimmune diabetes compared with type 2 diabetes. Further, we find that excess mortality mainly afflicted patients with poor glycaemic control. Also, fasting glucose levels (fasting glucose ≥ 8 mmol/L), another parameter of metabolic control, was associated with higher mortality risk. Mortality rates were similar for adult-onset autoimmune diabetes and type 2 diabetes, despite a clearly more favorable metabolic risk profile in individuals with autoimmune diabetes. Taken together, our results indicate that the effect of worse

metabolic control is the major factor that increases mortality in adult-onset autoimmune diabetes and also in type 2 diabetes. In line with these results are findings from two recent Swedish studies in type 1 diabetes with young (≤ 30 years) onset (30,31) where a strong independent effect of poor glycaemic control on risk of heart failure and CVD mortality was reported.

Our conclusions appear valid also when applied only to LADA and largely extend the findings on LADA of a previous, smaller, study (18). All-cause mortality was increased by 50% for LADA patients compared with individuals without diabetes, corresponding to the results seen for the whole group of adult-onset autoimmune diabetes. In addition, we show that the excess mortality risk pertains to men and women and, in particular, to death from IHD.

The strengths of this study include the use of data from a large population-based study and a long and virtually complete follow-up. Also, Norway is among the countries with the best quality of CVD death certification according to the ICD coding (32). Furthermore, we were able to take into account a large number of factors with potential influence on mortality, including metabolic risk factors, lifestyle, and socioeconomic factors. Lastly, to the best of our knowledge, ours is the largest study so far on mortality in autoimmune diabetes in adults.

Among possible limitations, a single measurement of HbA_{1c}, as available here, is clearly suboptimal to repeated measures over time. Self-reporting of diabetes by questionnaire is another potential concern. A previous HUNT Study showed self-reporting was a valid method to identify known cases of diabetes (33), but individuals with undiagnosed diabetes will be missed. If the risk of not being diagnosed is related to diabetes type, this may affect the comparison between mortality in autoimmune diabetes versus type 2 diabetes. Specificity of the anti-GAD assay was calculated to be 100%; hence, individuals with type 2 diabetes would not have been falsely classified as autoimmune diabetes. However, a sensitivity of 64% means that some autoimmune diabetes may be classified as type 2 diabetes. Given that the proportion of autoimmune diabetes is much lower than that of type 2 diabetes, this misclassification is unlikely to distort the association between diabetes type and mortality, which could have been the consequence of choosing a cutoff with higher sensitivity but less specificity, in which case, individuals with type 2 diabetes could have been wrongly classified as having autoimmune diabetes.

Noteworthy is that levels of anti-GAD in juvenile-onset autoimmune diabetes often diminish or disappear with duration of diabetes. However, there are indications that GAD levels are more persistent in LADA (34,35) than in type 1 diabetes in children (36,37). A previous study (34) showed that most individuals who developed LADA between HUNT2 and HUNT3 were GAD-positive already at HUNT2 (i.e., during prediabetes), with no significant change in GAD levels between HUNT2 and HUNT3.

Mortality was lower in HUNT participants compared with the general Norwegian population. Part of the explanation for this difference might be

that nonparticipation in HUNT was higher among those with poor health (38). One might speculate that individuals with better controlled diabetes are more prone to participate in a health study such as HUNT, and consequently, the diabetes-related mortality in our population may be an underestimation.

We conclude in this study, the largest so far on mortality in autoimmune diabetes with adult onset, that increased mortality risk in autoimmune diabetes in adults is at least of similar magnitude as seen for type 2 diabetes and that mortality is linked primarily to CVD. The increased risk appears to be associated primarily with poor glycemic control. These results highlight the need to improve treatment of hyperglycemia in autoimmune diabetes with adult onset.

Acknowledgments—The HUNT Study is a collaboration between the HUNT Research Centre (Faculty of Medicine, Norwegian University of Science and Technology, NTNU), the Nord-Trøndelag County Council, Norway, the Central Norway Health Authority, and the Norwegian Institute of Public Health. GlaxoSmithKline Norway supported the diabetes study at HUNT2 and HUNT3 financially through the Norwegian University of Science and Technology. This work was supported by a grant from the Swedish Council for Working Life and Social Research. No other potential conflicts of interest relevant to this article were reported.

All authors contributed to interpretation of results, reviewed and edited the manuscript, and approved the final version of the manuscript. L.O. contributed to developing the objective of the study, analyzed data, and was responsible for the writing of the manuscript. V.G. contributed to developing the objective of the study. K.M. researched data. T.A. analyzed data. S.C. contributed to developing the objective of the study. L.O. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

These data were presented at the 72nd Scientific Sessions of the American Diabetes Association, Philadelphia, Pennsylvania, 8–12 June 2012, and at the 48th Annual Meeting of the European Association for the Study of Diabetes, Berlin, Germany, 1–5 October 2012.

References

- Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992–1999. *Diabetologia* 2006;49:660–666
- Laing SP, Swerdlow AJ, Slater SD, et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. *Diabetologia* 2003;46:760–765
- Dale AC, Midthjell K, Nilsen TI, Wiseth R, Vatten LJ. Glycaemic control in newly diagnosed diabetes patients and mortality from ischaemic heart disease: 20-year follow-up of the HUNT Study in Norway. *Eur Heart J* 2009;30:1372–1377
- Sarwar N, Gao P, Seshasai SR, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *Lancet* 2010;375:2215–2222
- Aronson D. Hyperglycemia and the pathobiology of diabetic complications. *Adv Cardiol* 2008;45:1–16
- Bonora E, Targher G, Formentini G, et al. The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. *Diabet Med* 2004;21:52–58
- Eeg-Olofsson K, Cederholm J, Nilsson PM, et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. *Diabetologia* 2009;52:65–73
- Roper NA, Bilous RW, Kelly WF, Unwin NC, Connolly VM. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. *BMJ* 2001;322:1389–1393
- Tuomi T, Carlsson A, Li H, et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. *Diabetes* 1999;48:150–157
- Naik RG, Brooks-Worrell BM, Palmer JP. Latent autoimmune diabetes in adults. *J Clin Endocrinol Metab* 2009;94:4635–4644
- Hawa MI, Kolb H, Schloot N, et al.; Action LADA consortium. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. *Diabetes Care* 2013;36:908–913
- Groop L, Tuomi T, Rowley M, Zimmet P, Mackay IR. Latent autoimmune diabetes in adults (LADA)—more than a name. *Diabetologia* 2006;49:1996–1998
- Isomaa B, Almgren P, Henricsson M, et al. Chronic complications in patients with slowly progressing autoimmune type 1 diabetes (LADA). *Diabetes Care* 1999;22:1347–1353
- Römkens TE, Kusters GC, Netea MG, Netten PM. Prevalence and clinical characteristics of insulin-treated, anti-GAD-positive, type 2 diabetic subjects in an outpatient clinical department of a Dutch teaching hospital. *Neth J Med* 2006;64:114–118
- Buzzetti R, Di Pietro S, Giaccari A, et al.; Non Insulin Requiring Autoimmune Diabetes Study Group. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. *Diabetes Care* 2007;30:932–938
- Hawa MI, Thivolet C, Mauricio D, et al.; Action LADA Group. Metabolic syndrome and autoimmune diabetes: action LADA 3. *Diabetes Care* 2009;32:160–164
- Zhou Z, Xiang Y, Ji L, et al.; LADA China Study Group. Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study. *Diabetes* 2013;62:543–550
- Myhill P, Davis WA, Bruce DG, Mackay IR, Zimmet P, Davis TM. Chronic complications and mortality in community-based patients with latent autoimmune diabetes in adults: the Fremantle Diabetes Study. *Diabet Med* 2008;25:1245–1250
- Roh MO, Jung CH, Kim BY, Mok JO, Kim CH. The prevalence and characteristics of latent autoimmune diabetes in adults (LADA) and its relation with chronic complications in a clinical department of a university hospital in Korea. *Acta Diabetol* 2013;50:129–134.
- Andersen CD, Bennet L, Nyström L, et al. Worse glycaemic control in LADA patients than in those with type 2 diabetes, despite a longer time on insulin therapy. *Diabetologia* 2013;56:252–258
- Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects. *Diabetes Care* 2008;31:714–719
- Carnethon MR, De Chavez PJ, Biggs ML, et al. Association of weight status with mortality in adults with incident diabetes. *JAMA* 2012;308:581–590
- Krokstad S, Langhammer A, Hveem K, et al. Cohort Profile: The HUNT Study, Norway. *Int J Epidemiol* 9 August 2012 [Epub ahead of print]
- Nauman J, Janszky I, Vatten LJ, Wisløff U. Temporal changes in resting heart rate and deaths from ischemic heart disease. *JAMA* 2011;306:2579–2587
- Olsson L, Ahlbom A, Grill V, Midthjell K, Carlsson S. High levels of education are associated with an increased risk of latent autoimmune diabetes in adults: results from the Nord-Trøndelag health study. *Diabetes Care* 2011;34:102–107
- Fourlanos S, Dotta F, Greenbaum CJ, et al. Latent autoimmune diabetes in adults (LADA) should be less latent. *Diabetologia* 2005;48:2206–2212
- Alberti KG, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A Consensus Statement from the

- International Diabetes Federation. *Diabet Med* 2006;23:469–480
28. Cologne J, Hsu WL, Abbott RD, et al. Proportional hazards regression in epidemiologic follow-up studies: an intuitive consideration of primary time scale. *Epidemiology* 2012;23:565–573
29. World Health Organization Mortality Database. Available from http://www.who.int/healthinfo/mortality_data/en/index.html. Accessed 15 April 2012
30. Lind M, Bounias I, Olsson M, Gudbjörnsdóttir S, Svensson AM, Rosengren A. Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. *Lancet* 2011;378:140–146
31. Eeg-Olofsson K, Cederholm J, Nilsson PM, et al. Glycemic control and cardiovascular disease in 7,454 patients with type 1 diabetes: an observational study from the Swedish National Diabetes Register (NDR). *Diabetes Care* 2010;33:1640–1646
32. Lozano R, Murray CJL, Lopez AD, Satoh T. Miscoding and misclassification of ischemic heart disease mortality. In *Global Programme on Evidence for Health Policy working paper No. 12*. Geneva, Switzerland, World Health Organization, 2001.
33. Midthjell K, Holmen J, Bjørndal A, Lund-Larsen G. Is questionnaire information valid in the study of a chronic disease such as diabetes? The Nord-Trøndelag diabetes study. *J Epidemiol Community Health* 1992;46:537–542
34. Sorgjerd EP, Skorpen F, Kvaløy K, Midthjell K, Grill V. Time dynamics of autoantibodies are coupled to phenotypes and add to the heterogeneity of autoimmune diabetes in adults: the HUNT study, Norway. *Diabetologia* 2012;55:1310–1318
35. Borg H, Gottsäter A, Fernlund P, Sundkvist G. A 12-year prospective study of the relationship between islet antibodies and beta-cell function at and after the diagnosis in patients with adult-onset diabetes. *Diabetes* 2002;51:1754–1762
36. Decochez K, Keymeulen B, Somers G, et al.; Belgian Diabetes Registry. Use of an islet cell antibody assay to identify type 1 diabetic patients with rapid decrease in C-peptide levels after clinical onset. *Belgian Diabetes Registry. Diabetes Care* 2000;23:1072–1078
37. Decochez K, Tits J, Coolens JL, et al. High frequency of persisting or increasing islet-specific autoantibody levels after diagnosis of type 1 diabetes presenting before 40 years of age. The Belgian Diabetes Registry. *Diabetes Care* 2000;23:838–844
38. Langhammer A, Krokstad S, Romundstad P, Heggland J, Holmen J. The HUNT study: participation is associated with survival and depends on socioeconomic status, diseases and symptoms. *BMC Med Res Methodol* 2012;12:143